Dr. Reddy’s Laboratories has introduced Toripalimab (brand name Zytorvi) in India, marking the country’s third access to this innovative PD-1 inhibitor. The drug is approved for treating recurrent or metastatic nasopharyngeal carcinoma (NPC), offering a new treatment option that has shown a 48% reduction in disease progression or death risk.
According to GLOBOCAN 2022 data, over 120,000 NPC cases were diagnosed worldwide in 2022, with 6,519 cases in India. The drug is particularly significant for patients in advanced stages of this rare head and neck cancer, especially in northeastern Indian states with high NPC incidence.
The launch follows Dr. Reddy’s licensing agreement with Shanghai Junshi Biosciences, granting exclusive rights to develop and commercialize Toripalimab in 21 countries. This introduction aligns with the company’s oncology focus and commitment to expanding patient access to innovative treatments.
